Increased frequency of proangiogenic tunica intima endothelial kinase 2 (Tie2) expressing monocytes in individuals with type 2 diabetes mellitus.
Angiogenesis
Atherosclerosis
Macrovascular disease
Monocyte heterogeneity
Monocytes
Tie2
Type 2 diabetes mellitus
Journal
Cardiovascular diabetology
ISSN: 1475-2840
Titre abrégé: Cardiovasc Diabetol
Pays: England
ID NLM: 101147637
Informations de publication
Date de publication:
12 05 2022
12 05 2022
Historique:
received:
29
12
2021
accepted:
18
02
2022
entrez:
13
5
2022
pubmed:
14
5
2022
medline:
18
5
2022
Statut:
epublish
Résumé
Individuals with type 2 diabetes mellitus (T2DM) have an increased risk for developing macrovascular disease (MVD) manifested by atherosclerosis. Phenotypically and functionally different monocyte subsets (classical; CD14 Individuals with (N = 51) and without (N = 56) T2DM were recruited and allocated to "non-MVD" or "with MVD" (i.e., peripheral or coronary artery disease) subgroups. Blood monocyte subsets were quantified based on CD14, CD16 and Tie2 expression levels. Plasma levels of Tie2-ligands angiopoietin-1 and angiopoietin-2 were determined using ELISA. Carotid endarterectomy samples from individuals with (N = 24) and without (N = 22) T2DM were stained for intraplaque CD68 Monocyte counts were similar between individuals with T2DM and healthy controls (non-diabetic, non-MVD). Non-classical monocytes were reduced (p < 0.05) in T2DM, whereas the percentage of TEMs within the intermediate subset was increased (p < 0.05). T2DM was associated with increased angiopoietin-1 (p < 0.05) and angiopoietin-2 (p = 0.0001) levels. Angiopoietin-2 levels were higher in T2DM individuals with MVD compared with non-MVD (p < 0.01). Endarterectomized plaques showed no differences in macrophage influx and microvessel number between individuals with and without T2DM. Monocyte subset distribution is altered in T2DM with reduced non-classical monocytes and increased TEM percentage in the intermediate monocyte subset. Increased angiopoietin-2 levels together with increased frequency of TEMs might promote plaque vulnerability in T2DM which could however not be confirmed at tissue level in advanced atherosclerotic lesions.
Sections du résumé
BACKGROUND
Individuals with type 2 diabetes mellitus (T2DM) have an increased risk for developing macrovascular disease (MVD) manifested by atherosclerosis. Phenotypically and functionally different monocyte subsets (classical; CD14
METHODS
Individuals with (N = 51) and without (N = 56) T2DM were recruited and allocated to "non-MVD" or "with MVD" (i.e., peripheral or coronary artery disease) subgroups. Blood monocyte subsets were quantified based on CD14, CD16 and Tie2 expression levels. Plasma levels of Tie2-ligands angiopoietin-1 and angiopoietin-2 were determined using ELISA. Carotid endarterectomy samples from individuals with (N = 24) and without (N = 22) T2DM were stained for intraplaque CD68
RESULTS
Monocyte counts were similar between individuals with T2DM and healthy controls (non-diabetic, non-MVD). Non-classical monocytes were reduced (p < 0.05) in T2DM, whereas the percentage of TEMs within the intermediate subset was increased (p < 0.05). T2DM was associated with increased angiopoietin-1 (p < 0.05) and angiopoietin-2 (p = 0.0001) levels. Angiopoietin-2 levels were higher in T2DM individuals with MVD compared with non-MVD (p < 0.01). Endarterectomized plaques showed no differences in macrophage influx and microvessel number between individuals with and without T2DM.
CONCLUSIONS
Monocyte subset distribution is altered in T2DM with reduced non-classical monocytes and increased TEM percentage in the intermediate monocyte subset. Increased angiopoietin-2 levels together with increased frequency of TEMs might promote plaque vulnerability in T2DM which could however not be confirmed at tissue level in advanced atherosclerotic lesions.
Identifiants
pubmed: 35549955
doi: 10.1186/s12933-022-01497-6
pii: 10.1186/s12933-022-01497-6
pmc: PMC9102255
doi:
Substances chimiques
Angiopoietin-1
0
Angiopoietin-2
0
Receptor, TIE-2
EC 2.7.10.1
TEK protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
72Informations de copyright
© 2022. The Author(s).
Références
Cancer Cell. 2005 Sep;8(3):211-26
pubmed: 16169466
Br J Ophthalmol. 2004 Dec;88(12):1543-6
pubmed: 15548809
Am J Pathol. 2011 Nov;179(5):2651-9
pubmed: 21924227
JAMA. 2002 May 15;287(19):2570-81
pubmed: 12020339
Blood. 2010 Oct 21;116(16):e74-80
pubmed: 20628149
Circ Res. 2020 Nov 6;127(11):1437-1455
pubmed: 32981416
Front Pharmacol. 2019 Jun 13;10:666
pubmed: 31249530
Thromb Haemost. 2012 Nov;108(5):804-11
pubmed: 22918193
Arterioscler Thromb Vasc Biol. 2005 Oct;25(10):2054-61
pubmed: 16037567
Thromb Haemost. 2010 Aug;104(2):412-4
pubmed: 20431842
Mol Med. 2009 May-Jun;15(5-6):152-9
pubmed: 19295918
Diabetologia. 2012 Sep;55(9):2501-12
pubmed: 22648662
Cardiovasc Diabetol. 2004 Feb 04;3:1
pubmed: 14761253
J Endocrinol Invest. 2016 Nov;39(11):1235-1246
pubmed: 27344309
J Immunol. 2007 Jun 1;178(11):7405-11
pubmed: 17513791
Cell. 1996 Dec 27;87(7):1171-80
pubmed: 8980224
J Cereb Blood Flow Metab. 2009 May;29(5):994-1002
pubmed: 19293821
J Am Coll Cardiol. 2012 Oct 16;60(16):1512-20
pubmed: 22999728
Blood. 1993 Nov 15;82(10):3170-6
pubmed: 7693040
Cancer Res. 2010 Jul 1;70(13):5270-80
pubmed: 20530679
Arterioscler Thromb Vasc Biol. 2019 Jan;39(1):25-36
pubmed: 30580568
Stem Cells Dev. 2020 Jul;29(14):911-918
pubmed: 32423362
Atherosclerosis. 2014 Jun;234(2):311-9
pubmed: 24726899
Blood. 2007 Jun 15;109(12):5276-85
pubmed: 17327411
N Engl J Med. 1999 Jan 14;340(2):115-26
pubmed: 9887164
Thromb Haemost. 2011 Nov;106(5):757-62
pubmed: 21901241
Stem Cell Res Ther. 2016 May 23;7(1):75
pubmed: 27216150
Thromb Haemost. 2004 Aug;92(2):419-24
pubmed: 15269840
J Clin Endocrinol Metab. 2019 Jul 1;104(7):2623-2636
pubmed: 31102457
J Am Coll Cardiol. 2009 Apr 28;53(17):1517-27
pubmed: 19389562
J Clin Invest. 2003 Apr;111(8):1118-20
pubmed: 12697729
Atherosclerosis. 2012 Dec;225(2):461-8
pubmed: 23078881
J Am Coll Cardiol. 2009 Feb 3;53(5 Suppl):S35-42
pubmed: 19179216
Eur J Epidemiol. 2004;19(12):1127-33
pubmed: 15678794
J Thromb Haemost. 2011 May;9(5):1056-66
pubmed: 21342432
Eur Heart J. 2011 Jan;32(1):84-92
pubmed: 20943670
Immunol Res. 2012 Sep;53(1-3):41-57
pubmed: 22430559
J Atheroscler Thromb. 2020 May 1;27(5):441-448
pubmed: 31588100
BMC Genomics. 2009 Aug 27;10:403
pubmed: 19712453
J Am Coll Cardiol. 2014 Jan 7-14;63(1):1-11
pubmed: 24140662
Diabetes. 2005 Sep;54(9):2779-86
pubmed: 16123369
Eur J Clin Invest. 2013 Feb;43(2):121-30
pubmed: 23240665
Arterioscler Thromb Vasc Biol. 2004 Jul;24(7):1266-71
pubmed: 15142859
Mediators Inflamm. 2012;2012:649083
pubmed: 23316106
Diabetologia. 2013 Aug;56(8):1856-66
pubmed: 23616239
Immunity. 2018 Oct 16;49(4):595-613
pubmed: 30332628
EMBO Mol Med. 2013 Jun;5(6):858-69
pubmed: 23653322
J Mol Cell Cardiol. 2019 Feb;127:260-269
pubmed: 30629987
J Leukoc Biol. 2007 Mar;81(3):584-92
pubmed: 17135573
Circulation. 2002 Mar 5;105(9):1135-43
pubmed: 11877368
Atherosclerosis. 2007 Dec;195(2):e69-75
pubmed: 17606258
Diabetes Care. 2004 Dec;27(12):2918-24
pubmed: 15562207
Biochim Biophys Acta. 2009 Aug;1796(1):5-10
pubmed: 19362584
Nat Rev Immunol. 2005 Dec;5(12):953-64
pubmed: 16322748
Front Immunol. 2014 Oct 17;5:514
pubmed: 25368618
Immunobiology. 2012 May;217(5):476-82
pubmed: 22325375
Arterioscler Thromb Vasc Biol. 2011 Oct;31(10):2322-30
pubmed: 21799175
Front Cardiovasc Med. 2021 Feb 17;8:640124
pubmed: 33681309
Arthritis Rheum. 2002 Oct;46(10):2578-86
pubmed: 12384915
Matrix Biol. 2001 Sep;20(5-6):319-25
pubmed: 11566266
Inflamm Bowel Dis. 2007 May;13(5):566-72
pubmed: 17260384